Exchange Bulletin
Medicenna Therapeutics Corp. (MDNA) To Trade On Toronto Stock Exchange
Issuer: | Medicenna Therapeutics Corp. ("Medicenna") |
Security: | Common Shares (the "Shares") |
Symbol: | MDNA |
Number of securities issued and outstanding: | 24,344,048 Shares |
Number of securities reserved for issuance: | 5,732,309 Shares |
Listing category: | Industrial, Non-Exempt Issuer |
CUSIP: | 58490H 10 7 |
Trading currency: | CDN$ |
Listing and posted for trading date: | August 2, 2017 (at the opening) |
Other market(s): | The Shares have been listed on TSX Venture Exchange ("TSXV") since March 8, 2017 and traded under the symbol "MDNA". The Shares will be delisted from TSXV on August 2, 2017, upon commencement of trading on Toronto Stock Exchange. |
Temporary market maker: | Integral Wealth Securities Limited |
Investor relations: | Fahar Merchant Chief Executive Officer and President (604) 671-6673 Email : fmerchant@medicenna.com -and- Elizabeth Williams Chief Financial Officer (416) 648-5555 Email : ewilliams@medicenna.com |
Incorporation: | Business Corporations Act (Alberta) |
Fiscal year end: | March 31 |
Nature of business: | Medicenna is a clinical stage immunotherapy company developing proprietary super agonist and antagonist versions of cytokines called SuperkinesTM. MDNA55 is the Medicenna's lead Empowered CytokinesTM in clinical development for the treatment of brain cancers. |
Transfer agent and registrar: | TSX Trust Company at its principal office in Toronto |
Dividends: | None anticipated in the foreseeable future |
Sponsorship: | Bloom Burton Securities Inc. |
TSX contact: | Julie K. Shin, Director, Listed Issuer Services, Toronto Stock Exchange |